Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Sep;104(1):183–189. doi: 10.1111/j.1476-5381.1991.tb12405.x

Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.

M O den Boer 1, J P Heiligers 1, P R Saxena 1
PMCID: PMC1908277  PMID: 1664762

Abstract

1. Though it is well known that the antimigraine drugs ergotamine and dihydroergotamine reduce carotid arteriovenous anastomotic shunting, it is uncertain whether a 5-HT1-like receptor is responsible for this effect. Using a high dose of methiothepin (3 mg kg-1), which completely blocks the carotid vascular effects of sumatriptan, we have attempted to study the role of 5-HT1-like receptors in the carotid vascular effects of ergotamine as well as dihydroergotamine in anaesthetized pigs. 2. Both ergotamine and dihydroergotamine increased arterial blood pressure and decreased heart rate. 3. The ergot alkaloids reduced dose-dependently total carotid blood flow and conductance as a result of a selective decrease in the arteriovenous anastomotic fraction. The nutrient fraction increased, particularly to bones, tongue and salivary glands with ergotamine and to ears, head skin, bones and salivary glands with dihydroergotamine. In contrast, dural vascular conductance tended to decrease. 4. Methiothepin (3 mg kg-1) partially antagonized the decrease in total carotid and arteriovenous anastomotic blood flow and conductance by the ergot alkaloids; the ED30 for ergotamine and dihydroergotamine (agonist dose eliciting a 30% decrease in arteriovenous anastomotic conductance) was raised by 3.1 and 5.2 fold respectively. 5. These results indicate that the effects of ergotamine and dihydroergotamine are partly mediated by methiothepin-sensitive receptors, which may probably belong to either 5-HT1-like or alpha 2-adrenoceptor category. However, an important part of the effect of ergot alkaloids is left after methiothepin and this could be mediated by other, perhaps novel, receptors.

Full text

PDF
183

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Hurula V., Myllylä V. V., Arvela P., Kärki N. T., Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol. 1979 Nov;16(5):355–360. doi: 10.1007/BF00605636. [DOI] [PubMed] [Google Scholar]
  2. Andersen A. R., Tfelt-Hansen P., Lassen N. A. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987 Jan-Feb;18(1):120–123. doi: 10.1161/01.str.18.1.120. [DOI] [PubMed] [Google Scholar]
  3. Bom A. H., Heiligers J. P., Saxena P. R., Verdouw P. D. Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors. Br J Pharmacol. 1989 Jun;97(2):383–390. doi: 10.1111/j.1476-5381.1989.tb11965.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bom A. H., Verdouw P. D., Saxena P. R. Carotid haemodynamics in pigs during infusions of 8-OH-DPAT: reduction in arteriovenous shunting is mediated by 5-HT1-like receptors. Br J Pharmacol. 1989 Jan;96(1):125–132. doi: 10.1111/j.1476-5381.1989.tb11792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bom A. H., Villalón C. M., Verdouw P. D., Saxena P. R. The 5-HT1-like receptor mediating reduction of porcine carotid arteriovenous shunting by RU 24969 is not related to either the 5-HT1A or the 5-HT1B subtype. Eur J Pharmacol. 1989 Nov 14;171(1):87–96. doi: 10.1016/0014-2999(89)90432-9. [DOI] [PubMed] [Google Scholar]
  6. Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P., Middlemiss D. N., Mylecharane E. J., Richardson B. P., Saxena P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986 Jun;25(6):563–576. doi: 10.1016/0028-3908(86)90207-8. [DOI] [PubMed] [Google Scholar]
  7. Buzzi M. G., Moskowitz M. A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990 Jan;99(1):202–206. doi: 10.1111/j.1476-5381.1990.tb14679.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dallas F. A., Dixon C. M., McCulloch R. J., Saynor D. A. The kinetics of 14C-GR43175 in rat and dog. Cephalalgia. 1989;9 (Suppl 9):53–56. doi: 10.1111/J.1468-2982.1989.TB00073.X. [DOI] [PubMed] [Google Scholar]
  9. De Keyser J., Ebinger G., De Backer J. P., Convents A., Vanderheyden P., Vauquelin G. Subtypes of adrenergic and dopaminergic receptors in bovine cerebral blood vessels. Neurosci Lett. 1988 Feb 29;85(2):272–276. doi: 10.1016/0304-3940(88)90364-3. [DOI] [PubMed] [Google Scholar]
  10. Feniuk W., Humphrey P. P., Perren M. J., Connor H. E., Whalley E. T. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol. 1991;238 (Suppl 1):S57–S61. doi: 10.1007/BF01642908. [DOI] [PubMed] [Google Scholar]
  11. Glusa E., Markwardt F. Influence of endothelium on the vasoconstrictor effect of dihydroergotamine in the isolated rat aorta. Arch Int Pharmacodyn Ther. 1988 Nov-Dec;296:66–75. [PubMed] [Google Scholar]
  12. Goadsby P. J., Gundlach A. L. Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol. 1991 Jan;29(1):91–94. doi: 10.1002/ana.410290116. [DOI] [PubMed] [Google Scholar]
  13. HARRIS P., BISHOP J. M., SEGEL N. THE EFFECTS OF DIHYDROERGOTAMINE TARTRATE ON THE PULMONARY AND SYSTEMIC CIRCULATIONS IN MAN. Clin Sci. 1963 Dec;25:443–447. [PubMed] [Google Scholar]
  14. Hovdal H., Syversen G. B., Rosenthaler J. Ergotamine in plasma and CSF after i.m. and rectal administration to humans. Cephalalgia. 1982 Sep;2(3):145–150. doi: 10.1046/j.1468-2982.1982.0203145.x. [DOI] [PubMed] [Google Scholar]
  15. Humphrey P. P., Feniuk W., Perren M. J., Connor H. E., Oxford A. W., Coates L. H., Butina D. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988 Aug;94(4):1123–1132. doi: 10.1111/j.1476-5381.1988.tb11630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Iversen H. K., Nielsen T. H., Olesen J., Tfelt-Hansen P. Arterial responses during migraine headache. Lancet. 1990 Oct 6;336(8719):837–839. doi: 10.1016/0140-6736(90)92339-j. [DOI] [PubMed] [Google Scholar]
  17. Johnston B. M., Saxena P. R. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol. 1978 Jul;63(3):541–549. doi: 10.1111/j.1476-5381.1978.tb07810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kanto J., Allonen H., Koski K., Koulu M., Lammintausta R., Mäntylä R., Kleimola T., Siirtola T. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol. 1981 Mar;19(3):127–130. [PubMed] [Google Scholar]
  19. Kerber C. W., Newton T. H. The macro and microvasculature of the dura mater. Neuroradiology. 1973 Dec;6(4):175–179. doi: 10.1007/BF00335317. [DOI] [PubMed] [Google Scholar]
  20. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  21. MacLennan S. J., Martin G. R. Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction. Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):120–129. doi: 10.1007/BF00166953. [DOI] [PubMed] [Google Scholar]
  22. Markowitz S., Saito K., Moskowitz M. A. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia. 1988 Jun;8(2):83–91. doi: 10.1046/j.1468-2982.1988.0802083.x. [DOI] [PubMed] [Google Scholar]
  23. McCarthy B. G., Peroutka S. J. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache. 1989 Jul;29(7):420–422. doi: 10.1111/j.1526-4610.1989.hed2907420.x. [DOI] [PubMed] [Google Scholar]
  24. Müller-Schweinitzer E., Rosenthaler J. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol. 1987 Jun;9(6):686–693. [PubMed] [Google Scholar]
  25. Müller H., Glusa E., Markwardt F. Dual effect of dihydroergotamine at vascular 5-hydroxytryptamine receptors in pithed rats. Pharmacology. 1988;37(4):248–253. doi: 10.1159/000138473. [DOI] [PubMed] [Google Scholar]
  26. Nordenfelt I., Mellander S. Central haemodynamic effects of dihydroergotamine in patients with orthostatic hypotension. Acta Med Scand. 1972 Jan-Feb;191(1-2):115–120. [PubMed] [Google Scholar]
  27. Parsons A. A., Whalley E. T., Feniuk W., Connor H. E., Humphrey P. P. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol. 1989 Feb;96(2):434–440. doi: 10.1111/j.1476-5381.1989.tb11835.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Perren M. J., Feniuk W., Humphrey P. P. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia. 1989;9 (Suppl 9):41–46. doi: 10.1111/J.1468-2982.1989.TB00071.X. [DOI] [PubMed] [Google Scholar]
  29. ROWBOTHAM G. F., LITTLE E. NEW CONCEPTS ON THE AETIOLOGY AND VASCULARIZATION OF MENINGIOMATA; THE MECHANISM OF MIGRAINE; THE CHEMICAL PROCESSES OF THE CEREBROSPINAL FLUID; AND THE FORMATION OF COLLECTIONS OF BLOOD OR FLUID IN THE SUBDURAL SPACE. Br J Surg. 1965 Jan;52:21–24. doi: 10.1002/bjs.1800520105. [DOI] [PubMed] [Google Scholar]
  30. Roquebert J., Grenié B. Alpha 2-adrenergic agonist and alpha 1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch Int Pharmacodyn Ther. 1986 Nov;284(1):30–37. [PubMed] [Google Scholar]
  31. Saito K., Markowitz S., Moskowitz M. A. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol. 1988 Dec;24(6):732–737. doi: 10.1002/ana.410240607. [DOI] [PubMed] [Google Scholar]
  32. Saxena P. R., Bom A. H., Verdouw P. D. Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia. 1989;9 (Suppl 9):15–22. doi: 10.1111/J.1468-2982.1989.TB00068.X. [DOI] [PubMed] [Google Scholar]
  33. Saxena P. R., Cairo-Rawlins W. I. Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur J Pharmacol. 1979 Oct 1;58(3):305–312. doi: 10.1016/0014-2999(79)90479-5. [DOI] [PubMed] [Google Scholar]
  34. Saxena P. R., Den Boer M. O. Pharmacology of antimigraine drugs. J Neurol. 1991;238 (Suppl 1):S28–S35. doi: 10.1007/BF01642903. [DOI] [PubMed] [Google Scholar]
  35. Saxena P. R., Duncker D. J., Bom A. H., Heiligers J., Verdouw P. D. Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: evidence for the presence of "5-hydroxytryptamine1-like" receptors. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jul;333(3):198–204. doi: 10.1007/BF00512930. [DOI] [PubMed] [Google Scholar]
  36. Saxena P. R., Ferrari M. D. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci. 1989 May;10(5):200–204. doi: 10.1016/0165-6147(89)90238-1. [DOI] [PubMed] [Google Scholar]
  37. Saxena P. R., Koedam N. A., Heiligers J., Hof R. P. Ergotamine-induced constriction of cranial arteriovenous anastomoses in dogs pretreated with phentolamine and pizotifen. Cephalalgia. 1983 Jun;3(2):71–81. doi: 10.1046/j.1468-2982.1983.0302071.x. [DOI] [PubMed] [Google Scholar]
  38. Saxena P. R., Schamhardt H. C., Forsyth R. P., Hoeve J. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed. 1980 Dec;12(2-3):63–84. doi: 10.1016/0010-468x(80)90053-7. [DOI] [PubMed] [Google Scholar]
  39. Saxena P. R., Verdouw P. D. Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol. 1984 Aug;82(4):817–826. doi: 10.1111/j.1476-5381.1984.tb16478.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Saxena P. R., de Vlaam-Schluter G. M. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine. Headache. 1974 Jan;13(4):142–163. doi: 10.1111/j.1526-4610.1974.hed1304142.x. [DOI] [PubMed] [Google Scholar]
  41. Schamhardt H. C., Verdouw P. D., van der Hoek T. M., Saxena P. R. Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis. J Cardiovasc Pharmacol. 1979 Nov-Dec;1(6):673–686. doi: 10.1097/00005344-197911000-00008. [DOI] [PubMed] [Google Scholar]
  42. Spierings E. L., Saxena P. R. Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology. 1980 Jul;30(7 Pt 1):696–701. doi: 10.1212/wnl.30.7.696. [DOI] [PubMed] [Google Scholar]
  43. Villalón C. M., Bom A. H., Heiligers J. P., Den Boer M. O., Saxena P. R. Constriction of porcine arteriovenous anastomoses by indorenate is unrelated to 5-HT1A, 5-HT1B, 5-HT1C or 5-HT1D receptor subtypes. Eur J Pharmacol. 1990 Nov 6;190(1-2):167–176. doi: 10.1016/0014-2999(90)94123-f. [DOI] [PubMed] [Google Scholar]
  44. den Boer M. O., Villalón C. M., Heiligers J. P., Humphrey P. P., Saxena P. R. Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol. 1991 Feb;102(2):323–330. doi: 10.1111/j.1476-5381.1991.tb12173.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES